Publication | Closed Access

Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment

HepatologyMedicineResorce TrialClinical TrialsPharmacotherapySurgeryLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaRecistand Recist 1.1Health Sciences